DK3291679T3 - Ændring af mikrobielle populationer og modificering af mikrobiota - Google Patents
Ændring af mikrobielle populationer og modificering af mikrobiota Download PDFInfo
- Publication number
- DK3291679T3 DK3291679T3 DK16719873.8T DK16719873T DK3291679T3 DK 3291679 T3 DK3291679 T3 DK 3291679T3 DK 16719873 T DK16719873 T DK 16719873T DK 3291679 T3 DK3291679 T3 DK 3291679T3
- Authority
- DK
- Denmark
- Prior art keywords
- modification
- microbiota
- microbial populations
- populations
- microbial
- Prior art date
Links
- 230000004048 modification Effects 0.000 title 2
- 238000012986 modification Methods 0.000 title 2
- 241000736262 Microbiota Species 0.000 title 1
- 230000000813 microbial effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/60—Isolated nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1507775.3A GB201507775D0 (en) | 2015-05-06 | 2015-05-06 | Products, uses & methods (3) |
GBGB1507776.1A GB201507776D0 (en) | 2015-05-06 | 2015-05-06 | Products, uses & methods (4) |
GBGB1507773.8A GB201507773D0 (en) | 2015-05-06 | 2015-05-06 | Products, uses & methods (1) |
GBGB1507774.6A GB201507774D0 (en) | 2015-05-06 | 2015-05-06 | Products, uses & methods (2) |
GBGB1508461.9A GB201508461D0 (en) | 2015-05-17 | 2015-05-17 | Products uses and methods (4.2) |
GBGB1509366.9A GB201509366D0 (en) | 2015-05-31 | 2015-05-31 | Products, uses & methods (6) |
GBGB1510891.3A GB201510891D0 (en) | 2015-06-20 | 2015-06-20 | Products, uses & methods (7) |
GBGB1518402.1A GB201518402D0 (en) | 2015-10-17 | 2015-10-17 | Products, uses & methods (8) |
GB1600417.8A GB2531454A (en) | 2016-01-10 | 2016-01-10 | Recombinogenic nucleic acid strands in situ |
GBGB1600418.6A GB201600418D0 (en) | 2016-01-10 | 2016-01-10 | Products, uses & methods (1.2) |
PCT/EP2016/059803 WO2016177682A1 (en) | 2015-05-06 | 2016-05-03 | Altering microbial populations & modifying microbiota |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3291679T3 true DK3291679T3 (da) | 2022-01-17 |
Family
ID=57217569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16719873.8T DK3291679T3 (da) | 2015-05-06 | 2016-05-03 | Ændring af mikrobielle populationer og modificering af mikrobiota |
Country Status (18)
Country | Link |
---|---|
US (27) | US9701964B2 (da) |
EP (10) | EP3461337A1 (da) |
JP (4) | JP2018515138A (da) |
KR (3) | KR102138209B1 (da) |
CN (2) | CN114099712A (da) |
AU (5) | AU2016257306B2 (da) |
CA (1) | CA2984975A1 (da) |
DE (1) | DE112016002056T5 (da) |
DK (1) | DK3291679T3 (da) |
ES (1) | ES2905525T3 (da) |
HK (1) | HK1245016A1 (da) |
IL (4) | IL283877B (da) |
NZ (1) | NZ738068A (da) |
PL (1) | PL3291679T3 (da) |
RU (1) | RU2017142352A (da) |
SG (1) | SG11201708706YA (da) |
SI (1) | SI3291679T1 (da) |
WO (1) | WO2016177682A1 (da) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
MX2015007550A (es) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas. |
US11135273B2 (en) | 2013-02-07 | 2021-10-05 | The Rockefeller University | Sequence specific antimicrobials |
WO2014124226A1 (en) | 2013-02-07 | 2014-08-14 | The Rockefeller University | Sequence specific antimicrobials |
KR20160034901A (ko) | 2013-06-17 | 2016-03-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물 |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
WO2015066119A1 (en) | 2013-10-30 | 2015-05-07 | North Carolina State University | Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri |
DK3079725T3 (da) | 2013-12-12 | 2020-01-20 | Broad Inst Inc | Administration, brug og terapeutiske anvendelser af crispr-cas-systemerne og sammensætninger til genomredigering |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
JP6625055B2 (ja) | 2013-12-12 | 2020-01-08 | ザ・ブロード・インスティテュート・インコーポレイテッド | 組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法 |
US10787654B2 (en) | 2014-01-24 | 2020-09-29 | North Carolina State University | Methods and compositions for sequence guiding Cas9 targeting |
CN106460003A (zh) | 2014-04-08 | 2017-02-22 | 北卡罗来纳州立大学 | 用于使用crispr相关基因rna引导阻遏转录的方法和组合物 |
WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
EP3633032A3 (en) | 2014-08-28 | 2020-07-29 | North Carolina State University | Novel cas9 proteins and guiding features for dna targeting and genome editing |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
EP3461337A1 (en) | 2015-05-06 | 2019-04-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
EP3303607A4 (en) | 2015-05-29 | 2018-10-10 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids |
CA2983874C (en) | 2015-06-15 | 2022-06-21 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials |
WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
EP3356533A1 (en) | 2015-09-28 | 2018-08-08 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
WO2017112620A1 (en) | 2015-12-22 | 2017-06-29 | North Carolina State University | Methods and compositions for delivery of crispr based antimicrobials |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
GB2573062A (en) | 2016-10-14 | 2019-10-23 | Harvard College | AAV delivery of nucleobase editors |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
US11267738B2 (en) * | 2017-04-24 | 2022-03-08 | Microbe Detectives Llc | Method of using microbial DNA sequencing in recovering renewable resources from wastewater and other waste streams |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US20230193241A1 (en) * | 2017-06-25 | 2023-06-22 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
GB201710126D0 (en) * | 2017-06-25 | 2017-08-09 | Snipr Tech Ltd | Vectors & Methods |
JP7231607B2 (ja) * | 2017-07-12 | 2023-03-01 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | プロバイオティクスの性質を有する弱毒生コレラワクチン |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
GB201712733D0 (en) * | 2017-08-08 | 2017-09-20 | Snipr Tech Ltd | Methods & cells |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2019055582A1 (en) * | 2017-09-12 | 2019-03-21 | Ubabiologix Corp. | COMPOSITIONS AND METHODS FOR SANITATION OF WASTE WATER |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
EP3714055A1 (en) | 2017-11-21 | 2020-09-30 | CRISPR Therapeutics AG | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
CN109899053B (zh) * | 2017-12-08 | 2022-02-01 | 中国石油天然气股份有限公司 | 钻井井场的确定方法、装置及计算机可读存储介质 |
CN109971778B (zh) * | 2017-12-27 | 2022-11-18 | 北京蓝晶微生物科技有限公司 | 一种在盐单胞菌中快速基因编辑的载体组合及其应用 |
CN108410880B (zh) * | 2018-01-26 | 2021-10-22 | 昆明理工大学 | 一种丹波黑大豆柠檬酸转运蛋白基因及其应用 |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
CN112292145A (zh) | 2018-03-25 | 2021-01-29 | 斯尼普生物群系有限公司 | 治疗和预防微生物感染 |
WO2019213592A1 (en) * | 2018-05-04 | 2019-11-07 | Locus Biosciences, Inc. | Methods and compositions for killing a target bacterium |
CN112941155B (zh) * | 2018-05-14 | 2023-07-14 | 北京艾克伦医疗科技有限公司 | 具有茎环结构的dna引物对及其应用 |
JP2021525105A (ja) * | 2018-05-25 | 2021-09-24 | ローカス バイオサイエンシーズ,インク. | 標的細菌を死滅させるための方法および組成物 |
CA3105867A1 (en) * | 2018-07-11 | 2020-01-16 | Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines S.E.C. | Bacterial conjugative system and therapeutic uses thereof |
CN109136128B (zh) * | 2018-08-23 | 2021-07-16 | 国家***第一海洋研究所 | 一种副球菌及其筛选方法和在合成银纳米颗粒中的应用 |
WO2020072248A1 (en) | 2018-10-01 | 2020-04-09 | North Carolina State University | Recombinant type i crispr-cas system |
US11851663B2 (en) * | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
CN111119818B (zh) * | 2018-10-30 | 2022-04-12 | 中国石油化工股份有限公司 | 一种油藏内源功能微生物定向调控的方法 |
WO2020146888A1 (en) * | 2019-01-11 | 2020-07-16 | The Trustees Of Columbia University In The City Of New York | Microbiome engineering through engineered mobile genetic elements |
GB201901099D0 (en) | 2019-01-27 | 2019-03-13 | Snipr Biome Aps | Methods, uses and compositions |
WO2020176624A1 (en) * | 2019-02-26 | 2020-09-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Probiotics and probiotic compositions having modified carbohydrate metabolism |
WO2020191153A2 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CN110499353B (zh) * | 2019-08-09 | 2023-11-07 | 佛山市第四人民医院(佛山市结核病防治所) | 一种用于结核耐药诊断的微生物标志物及其应用 |
GB201913045D0 (en) * | 2019-09-10 | 2019-10-23 | Univ Oxford Innovation Ltd | Biofilm transformation |
CN110596364B (zh) * | 2019-09-12 | 2020-06-23 | 江南大学 | 一种***特异性抗原检测的比率电化学传感器的构建方法及其应用 |
JP2022548735A (ja) * | 2019-09-18 | 2022-11-21 | アンシリア, インコーポレイテッド | マイクロバイオーム調節のための組成物及び方法 |
BR112022005831A2 (pt) * | 2019-09-30 | 2022-06-21 | Sigma Aldrich Co Llc | Modulação de composições de microbiota usando nucleases direcionadas |
WO2021092249A1 (en) * | 2019-11-06 | 2021-05-14 | Locus Biosciences, Inc. | Crispr cas systems and lysogeny modules |
CA3162622A1 (en) * | 2019-11-25 | 2021-06-03 | Baylor College Of Medicine | Selective expansion of gene-targeted cells |
US20230046246A1 (en) * | 2019-12-13 | 2023-02-16 | The Regents Of The University Of California | Reducing Antibiotic Resistance in Bacteria Using Pro-Active Genetics |
DE102020101859A1 (de) * | 2020-01-27 | 2021-07-29 | Oxana Karpf | Verfahren zur Reduktion der Population mindestens einer adipogenen Bakterienart umfassend Bakteriophagen sowie Bakteriophagen und deren Verwendung |
CA3171941A1 (en) * | 2020-03-16 | 2021-09-23 | Joseph E. Peters | Compositions and methods comprising improved guide rnas |
US20230147495A1 (en) * | 2020-03-27 | 2023-05-11 | Phuc Hong Vo | Genome engineering using crispr rna-guided integrases |
JP2021169579A (ja) * | 2020-04-16 | 2021-10-28 | 旭化成株式会社 | セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法 |
JP2021169578A (ja) * | 2020-04-16 | 2021-10-28 | 旭化成株式会社 | セルロース繊維乾燥体の製造方法、及び樹脂複合体の製造方法 |
JP7488096B2 (ja) * | 2020-04-16 | 2024-05-21 | 旭化成株式会社 | セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法 |
KR20230019843A (ko) | 2020-05-08 | 2023-02-09 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물 |
US20230181659A1 (en) * | 2020-05-14 | 2023-06-15 | Cz Biohub Sf, Llc | Phage-mediated delivery of genes to gut microbiome |
GB202007943D0 (en) | 2020-05-27 | 2020-07-08 | Snipr Biome Aps | Products & methods |
EP4164390A4 (en) * | 2020-06-16 | 2024-05-29 | Dsm Ip Assets Bv | COMPOSITION FOR REDUCING THE RISK OF URINARY TRACT INFECTION AND VAGINAL INFECTION IN WOMEN |
CN111849822A (zh) * | 2020-07-28 | 2020-10-30 | 上海海洋大学 | 对抗菌素敏感的非o1/o139型霍乱弧菌菌株及应用 |
WO2022081428A1 (en) * | 2020-10-16 | 2022-04-21 | Nubiyota Llc | Bacterial compositions and methods of use thereof for treatment of metabolic syndrome |
CN113201531B (zh) * | 2021-04-27 | 2023-06-27 | 隆平生物技术(海南)有限公司 | 转基因玉米事件lw2-1及其检测方法 |
WO2023012109A2 (en) * | 2021-08-01 | 2023-02-09 | Snipr Biome Aps | Microbiota engineering |
WO2023012785A1 (en) * | 2021-08-02 | 2023-02-09 | Trobix Innovation Ltd | Systems for modulating drug metabolism by cells, methods and compositions thereof |
CN114591879B (zh) * | 2022-05-11 | 2022-12-06 | 中国农业大学 | 一种抑制幽门螺杆菌的发酵乳杆菌及其应用 |
WO2024003301A1 (en) | 2022-06-29 | 2024-01-04 | Snipr Biome Aps | Targeting e coli cells |
WO2024023820A1 (en) * | 2022-07-25 | 2024-02-01 | Trobix Bio Ltd | Systems for modulating microbiome target cells, methods and compositions thereof |
WO2024086532A1 (en) * | 2022-10-17 | 2024-04-25 | Locus Biosciences, Inc. | Staphylococcus phage compositions and cocktails thereof |
CN116058432B (zh) * | 2023-03-02 | 2023-06-16 | 莱芜泰禾生化有限公司 | 一种柠檬酸菌丝渣微生物饲料添加剂及其制备方法和应用 |
Family Cites Families (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US928A (en) * | 1838-09-19 | Eccentbic bbake eob abbesting the motion of bailboad-cabs | ||
US3003323A (en) | 1958-01-29 | 1961-10-10 | Armco Steel Corp | Composite pile connector |
US4626504A (en) | 1983-07-01 | 1986-12-02 | Lubrizol Genetics, Inc. | DNA transfer vector for gram-negative bacteria |
SE8505027D0 (sv) | 1985-10-24 | 1985-10-24 | Kabigen Ab | A lytic virulent phage, a hostcell containing same and a process for protein production |
US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
DE4208785A1 (de) | 1992-03-19 | 1993-09-23 | Degussa | Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen |
EP0665852A1 (en) | 1993-07-09 | 1995-08-09 | Amgen Boulder Inc. | Recombinant ctla4 polypeptides and methods for making the same |
US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US20030049841A1 (en) | 1997-06-16 | 2003-03-13 | Short Jay M. | High throughput or capillary-based screening for a bioactivity or biomolecule |
KR100856446B1 (ko) | 1998-12-23 | 2008-09-04 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2430501A1 (en) | 2000-01-11 | 2001-07-19 | Intralytix, Inc. | Method for produce sanitation using bacteriophages |
AU2002365188A1 (en) | 2001-11-07 | 2003-07-30 | Musc Foundation For Research Development | Nucleic acid delivery and expression |
CA2396611A1 (en) | 2002-07-31 | 2004-01-31 | Plant Bioscience Limited | Materials and methods for generating genetic disruptions in bacterial cells |
KR101325023B1 (ko) | 2003-07-02 | 2013-11-04 | 노보 노르디스크 에이/에스 | Nk 세포 활성을 조절하기 위한 조성물 및 방법 |
HUE033129T2 (en) | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells |
US20070020240A1 (en) | 2003-10-06 | 2007-01-25 | Gangagen, Inc. | Defined dose therapeutic phage |
CA2562457A1 (en) | 2004-04-07 | 2006-07-20 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Reporter plasmid phage packaging system for detection of bacteria |
DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
US8222376B2 (en) | 2005-01-06 | 2012-07-17 | Novo Nordisk A/S | KIR-binding agents and methods of use thereof |
EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
DK2341149T3 (da) | 2005-08-26 | 2017-02-27 | Dupont Nutrition Biosci Aps | Anvendelse af CRISPR-associerede gener (Cas) |
CN101300272B (zh) | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
WO2007100098A1 (ja) | 2006-03-03 | 2007-09-07 | Kyoto University | 細胞表面機能分子の細胞外領域多量体 |
US8445639B2 (en) | 2006-05-15 | 2013-05-21 | Avidbiotics Corporation | Recombinant bacteriophage and methods for their use |
WO2008076696A2 (en) * | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
EP2109460B1 (en) | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
TR201905633T4 (tr) | 2007-03-02 | 2019-05-21 | Dupont Nutrition Biosci Aps | İyileştirilmiş faj direnci olan kültürler. |
WO2008121830A2 (en) | 2007-03-30 | 2008-10-09 | National Research Council Of Canada | Phage receptor binding proteins for antibacterial therapy and other novel uses |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
ES2639857T3 (es) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Anticuerpos monoclonales para el tratamiento del tumor |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
WO2010011961A2 (en) | 2008-07-25 | 2010-01-28 | University Of Georgia Research Foundation, Inc. | Prokaryotic rnai-like system and methods of use |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
JP5344895B2 (ja) * | 2008-12-10 | 2013-11-20 | 矢崎総業株式会社 | 充電監視装置 |
WO2010075424A2 (en) | 2008-12-22 | 2010-07-01 | The Regents Of University Of California | Compositions and methods for downregulating prokaryotic genes |
US8241498B2 (en) | 2009-03-28 | 2012-08-14 | Phage Biocontrol Research, Llc | Process for remediating biofouling in water systems with virulent bacteriophage |
WO2011014438A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
IN2012DN02753A (da) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
DK2536745T3 (da) | 2010-02-19 | 2016-08-22 | Xencor Inc | Novel ctla4-ig immunoadhæsiner |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US8252576B2 (en) | 2010-08-11 | 2012-08-28 | Phage Biocontrol Research, Llc | Use of prokaryote viruses to remediate bio-fouling |
WO2012054726A1 (en) * | 2010-10-20 | 2012-04-26 | Danisco A/S | Lactococcus crispr-cas sequences |
BR112013012138B1 (pt) | 2010-11-22 | 2022-02-22 | Innate Pharma Sa | Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir) |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US20180099001A1 (en) | 2011-04-29 | 2018-04-12 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
WO2012159023A2 (en) | 2011-05-19 | 2012-11-22 | Virginia Commonwealth University | Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction |
TWI560200B (en) | 2011-05-25 | 2016-12-01 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
WO2013025119A1 (ru) | 2011-08-18 | 2013-02-21 | Roschin Evgeniy Mikhailovich | Способ определения расположения протетической верхней плоскости у пациентов |
US20130121968A1 (en) | 2011-10-03 | 2013-05-16 | Atossa Genetics, Inc. | Methods of combining metagenome and the metatranscriptome in multiplex profiles |
DK3424947T3 (da) | 2011-10-28 | 2021-02-22 | Regeneron Pharma | Genmodificerede t-celle-receptor-mus |
ES2861435T3 (es) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
NZ701607A (en) | 2012-04-30 | 2017-04-28 | Sonomaceuticals Llc | Therapeutic use of chardonnay seed products |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
PE20150336A1 (es) | 2012-05-25 | 2015-03-25 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn |
WO2013187556A1 (en) | 2012-06-14 | 2013-12-19 | Scripps Korea Antibody Institute | Novel antibody specific for clec14a and uses thereof |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US10025647B2 (en) | 2012-06-30 | 2018-07-17 | Intel Corporation | Memory poisoning with hints |
AU2013289984B2 (en) | 2012-07-13 | 2018-03-08 | The Trustees Of The University Of Pennsylvania | Use of CART19 to deplete normal B cells to induce tolerance |
JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
US9460205B2 (en) * | 2012-07-20 | 2016-10-04 | Google Inc. | Crowdsourced video collaboration |
EP3808844A1 (en) | 2012-07-25 | 2021-04-21 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
JP6368308B2 (ja) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのvista調節剤 |
US11060148B2 (en) | 2012-10-16 | 2021-07-13 | Dana-Farber Cancer Institute, Inc. | Diagnosing and treating colorectal cancer |
EP3252160B1 (en) | 2012-12-12 | 2020-10-28 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
US11135273B2 (en) * | 2013-02-07 | 2021-10-05 | The Rockefeller University | Sequence specific antimicrobials |
WO2014124226A1 (en) * | 2013-02-07 | 2014-08-14 | The Rockefeller University | Sequence specific antimicrobials |
US9593339B1 (en) * | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
WO2014153194A2 (en) | 2013-03-14 | 2014-09-25 | Seres Health, Inc. | Methods for pathogen detection and enrichment from materials and compositions |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
JP6603209B2 (ja) | 2013-05-10 | 2019-11-06 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾 |
KR20160034901A (ko) | 2013-06-17 | 2016-03-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물 |
EP4023750A1 (en) | 2013-07-01 | 2022-07-06 | Massachusetts Institute of Technology | Functionalization of endogenous bacteria |
DE102013012448A1 (de) | 2013-07-26 | 2015-01-29 | Kuka Laboratories Gmbh | Verfahren und Vorrichtung zum Bremsen einer Roboterachsanordnung |
JP5729429B2 (ja) | 2013-07-29 | 2015-06-03 | トヨタ自動車株式会社 | 接合構造、及び接合構造の製造方法 |
AU2014296887A1 (en) | 2013-08-02 | 2016-01-28 | Aduro Biotech Holdings, Europe B.V. | Combining CD27 agonists and immune checkpoint inhibition for immune stimulation |
WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
EP3041498B1 (en) * | 2013-09-05 | 2022-02-16 | Massachusetts Institute of Technology | Tuning microbial populations with programmable nucleases |
US20150070747A1 (en) * | 2013-09-09 | 2015-03-12 | Qualcomm Mems Technologies, Inc. | Display element reset using polarity reversal |
ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
CN105637087A (zh) | 2013-09-18 | 2016-06-01 | 科马布有限公司 | 方法、细胞与生物体 |
WO2015048577A2 (en) * | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
KR102308597B1 (ko) | 2013-10-17 | 2021-10-01 | 내셔널 유니버시티 오브 싱가포르 | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 |
US10767156B2 (en) | 2013-10-24 | 2020-09-08 | Yeda Research And Development Co., Ltd. | Polynucleotides encoding BREX system polypeptides and methods of using same |
WO2015069682A2 (en) | 2013-11-05 | 2015-05-14 | President And Fellows Of Harvard College | Precise microbiota engineering at the cellular level |
CN106102730A (zh) | 2013-11-05 | 2016-11-09 | 天普大学高等教育联合体 | 作为抗微生物剂的聚阳离子两亲物 |
CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
US20150132263A1 (en) | 2013-11-11 | 2015-05-14 | Radiant Genomics, Inc. | Compositions and methods for targeted gene disruption in prokaryotes |
CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
EP2876167A1 (en) | 2013-11-21 | 2015-05-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
CN105980568B (zh) | 2013-12-11 | 2019-12-03 | 瑞泽恩制药公司 | 用于靶向修饰基因组的方法和组合物 |
JP6625055B2 (ja) * | 2013-12-12 | 2020-01-08 | ザ・ブロード・インスティテュート・インコーポレイテッド | 組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法 |
KR20160089526A (ko) | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | 입자 전달 성분을 이용한 표적 장애 및 질병에 대한 crispr-cas 시스템 및 조성물의 전달, 이용 및 치료 적용 |
US10351452B2 (en) | 2014-01-29 | 2019-07-16 | Synphagen Llc | Compositions for in vivo expression of therapeutic sequences in the microbiome |
US10287590B2 (en) | 2014-02-12 | 2019-05-14 | Dna2.0, Inc. | Methods for generating libraries with co-varying regions of polynuleotides for genome modification |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US20170173086A1 (en) | 2014-03-25 | 2017-06-22 | Ginkgo Bioworks, Inc. | Methods and Genetic Systems for Cell Engineering |
EP3122880B1 (en) * | 2014-03-26 | 2021-05-05 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
WO2015153940A1 (en) | 2014-04-03 | 2015-10-08 | Massachusetts Institute Of Technology | Methods and compositions for the production of guide rna |
CN106460003A (zh) | 2014-04-08 | 2017-02-22 | 北卡罗来纳州立大学 | 用于使用crispr相关基因rna引导阻遏转录的方法和组合物 |
HUE051354T2 (hu) * | 2014-04-14 | 2021-03-01 | Nemesis Bioscience Ltd | Terapeutikum |
GB201406968D0 (en) | 2014-04-17 | 2014-06-04 | Green Biologics Ltd | Deletion mutants |
GB201406970D0 (en) | 2014-04-17 | 2014-06-04 | Green Biologics Ltd | Targeted mutations |
US11584936B2 (en) | 2014-06-12 | 2023-02-21 | King Abdullah University Of Science And Technology | Targeted viral-mediated plant genome editing using CRISPR /Cas9 |
EP3166974A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
EP3633032A3 (en) | 2014-08-28 | 2020-07-29 | North Carolina State University | Novel cas9 proteins and guiding features for dna targeting and genome editing |
US11274317B2 (en) | 2014-09-05 | 2022-03-15 | Vilnius University | Targeted RNA knockdown and knockout by type III-A Csm complexes |
WO2016040892A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies |
AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
AU2015334468B2 (en) | 2014-10-23 | 2021-06-17 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
EP3224353B9 (en) | 2014-11-26 | 2023-08-09 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Targeted elimination of bacterial genes |
WO2016183531A1 (en) | 2015-05-13 | 2016-11-17 | Synlogic, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
WO2016183532A1 (en) | 2015-05-13 | 2016-11-17 | Synlogic, Inc. | Bacteria engineered to treat a disease or disorder |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
US20160244784A1 (en) | 2015-02-15 | 2016-08-25 | Massachusetts Institute Of Technology | Population-Hastened Assembly Genetic Engineering |
BR112017018656B1 (pt) | 2015-03-02 | 2021-11-30 | Synlogic, Inc | Bactéria geneticamente modificada, composição farmaceuticamente aceitável compreendendo a dita bactéria e uso da dita composição para tratar ou prevenir uma doença ou condição associada à inflamação intestinal e/ou função da barreira intestinal comprometida |
EP3285777B1 (en) | 2015-04-23 | 2021-06-09 | Kaleido Biosciences, Inc. | Glycan therapeutics and methods of treatment |
GB2531454A (en) | 2016-01-10 | 2016-04-20 | Snipr Technologies Ltd | Recombinogenic nucleic acid strands in situ |
EP3461337A1 (en) | 2015-05-06 | 2019-04-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
US20160347836A1 (en) | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of hodgkin's lymphoma using an anti-pd-1 antibody |
MA43344A (fr) | 2015-05-29 | 2018-04-11 | Juno Therapeutics Inc | Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées |
EP3303607A4 (en) | 2015-05-29 | 2018-10-10 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids |
KR20240059639A (ko) | 2015-06-01 | 2024-05-07 | 더 유니버서티 오브 시카고 | 공생 미생물총의 조작에 의한 암의 치료 |
CA2983874C (en) | 2015-06-15 | 2022-06-21 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials |
US10648020B2 (en) | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
US20180200342A1 (en) | 2015-07-13 | 2018-07-19 | Institut Pasteur | Improving sequence-specific antimicrobials by blocking dna repair |
US20170216370A1 (en) | 2015-07-31 | 2017-08-03 | Synlogic, Inc. | Bacteria engineered to treat disorders involving propionate catabolism |
GB201514510D0 (en) | 2015-08-14 | 2015-09-30 | Nemesis Bioscience Ltd | Delivery vehicle |
KR102581908B1 (ko) | 2015-09-10 | 2023-09-22 | 위니베르시트카솔리끄드루뱅 | 대사장애를 치료하기 위한 저온살균된 아커만시아의 용도 |
EP3356533A1 (en) | 2015-09-28 | 2018-08-08 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
EP3988107A1 (en) | 2015-10-30 | 2022-04-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
US11473104B2 (en) | 2015-12-04 | 2022-10-18 | Massachusetts Institute Of Technology | Engineered phagemids |
CN108430993A (zh) | 2015-12-17 | 2018-08-21 | 吉利德科学公司 | Tank-结合激酶抑制剂化合物 |
WO2017112620A1 (en) | 2015-12-22 | 2017-06-29 | North Carolina State University | Methods and compositions for delivery of crispr based antimicrobials |
JP2019505511A (ja) | 2016-01-06 | 2019-02-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 |
WO2017123418A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
US20190010506A1 (en) | 2016-01-11 | 2019-01-10 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
US20190282628A1 (en) | 2016-01-11 | 2019-09-19 | Synlogic Inc. | Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof |
WO2017136795A1 (en) | 2016-02-04 | 2017-08-10 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with tryptophan metabolism |
US20170247690A1 (en) | 2016-02-25 | 2017-08-31 | Agenovir Corporation | Oncoviral treatment with nuclease and chemotherapeutic |
AU2017228398A1 (en) | 2016-03-03 | 2018-10-18 | Cornell University | Small molecule IRE1-alpha inhibitors |
US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
US20190142881A1 (en) | 2016-04-25 | 2019-05-16 | Yale University | Bacteriophage compositions and uses thereof |
IL262772B2 (en) | 2016-05-06 | 2023-10-01 | Juno Therapeutics Inc | Genetically engineered cells and methods for their preparation |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
US11395838B2 (en) | 2016-09-27 | 2022-07-26 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
US10626394B2 (en) | 2016-10-28 | 2020-04-21 | Massachusetts Institute Of Technology | Synthetic bacteriophages and bacteriophage compositions |
WO2018112194A1 (en) | 2016-12-15 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
CN110582291A (zh) | 2016-12-22 | 2019-12-17 | 古斯达威罗斯研究所 | 抗pd1/pd-l1/pd-l2抗体的反应性标志物和功效改善用调节剂 |
US11149269B2 (en) | 2017-05-15 | 2021-10-19 | New York University | Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability |
EP3634442A4 (en) | 2017-05-24 | 2021-05-26 | Tets, Viktor, Veniaminovich | METHODS OF TREATMENT AND PREVENTION OF DISEASES |
US20200157237A1 (en) | 2017-05-25 | 2020-05-21 | The Broad Institute, Inc. | Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof |
WO2018217981A1 (en) | 2017-05-26 | 2018-11-29 | North Carolina State University | Altered guide rnas for modulating cas9 activity and methods of use |
US20200129570A1 (en) | 2017-06-02 | 2020-04-30 | Board Of Regents, The University Of Texas System | Specific Bacterial Species and Metabolite That Improves Immune Checkpoint Inhibitor Therapy Efficacy |
EP3634473A4 (en) | 2017-06-07 | 2021-03-24 | The Rockefeller University | REINFORCEMENT OF CRISPR GENEDITATION OR TARGET DESTRUCTION BY CO-EXPRESSION OF HETEROLOGICAL DNA REPAIR PROTEINS |
GB201710126D0 (en) | 2017-06-25 | 2017-08-09 | Snipr Tech Ltd | Vectors & Methods |
GB201712733D0 (en) | 2017-08-08 | 2017-09-20 | Snipr Tech Ltd | Methods & cells |
US10303379B2 (en) | 2017-09-25 | 2019-05-28 | International Business Machines Corporation | Efficient adaptive read-ahead in log structured storage |
US20190160120A1 (en) | 2017-11-29 | 2019-05-30 | Snipr Biome Aps | Dna, methods etc |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
WO2019213592A1 (en) | 2018-05-04 | 2019-11-07 | Locus Biosciences, Inc. | Methods and compositions for killing a target bacterium |
CA3102353A1 (en) | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
US20220056433A1 (en) | 2018-10-01 | 2022-02-24 | North Carolina State University | Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression |
WO2020072248A1 (en) | 2018-10-01 | 2020-04-09 | North Carolina State University | Recombinant type i crispr-cas system |
US20220177943A1 (en) | 2018-10-01 | 2022-06-09 | Rodolphe Barrangou | Recombinant type i crispr-cas system and uses thereof for screening for variant cells |
US20220170048A1 (en) | 2018-10-01 | 2022-06-02 | North Carolina State University | Recombinant type i crispr-cas system and uses thereof for killing target cells |
US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
US20220056457A1 (en) | 2018-12-11 | 2022-02-24 | The University Of Western Ontario | Cis conjugative plasmid system |
KR102227515B1 (ko) | 2018-12-18 | 2021-03-12 | 주식회사 포스코 | 제올라이트 및 그 제조방법 |
GB201901099D0 (en) | 2019-01-27 | 2019-03-13 | Snipr Biome Aps | Methods, uses and compositions |
US20220403357A1 (en) | 2019-11-12 | 2022-12-22 | The Broad Institute, Inc. | Small type ii cas proteins and methods of use thereof |
WO2022003209A1 (en) | 2020-07-03 | 2022-01-06 | Eligo Bioscience | Method of containment of nucleic acid vectors introduced in a microbiome population |
GB202015255D0 (en) | 2020-09-26 | 2020-11-11 | Snipr Biome Aps | Synthetic viruses |
-
2016
- 2016-05-03 EP EP18205170.6A patent/EP3461337A1/en not_active Withdrawn
- 2016-05-03 KR KR1020177034864A patent/KR102138209B1/ko active IP Right Grant
- 2016-05-03 ES ES16719873T patent/ES2905525T3/es active Active
- 2016-05-03 EP EP22194479.6A patent/EP4169383A1/en not_active Withdrawn
- 2016-05-03 DE DE112016002056.2T patent/DE112016002056T5/de active Pending
- 2016-05-03 RU RU2017142352A patent/RU2017142352A/ru not_active Application Discontinuation
- 2016-05-03 EP EP23162125.1A patent/EP4233546A3/en active Pending
- 2016-05-03 PL PL16719873T patent/PL3291679T3/pl unknown
- 2016-05-03 CN CN202111384643.7A patent/CN114099712A/zh active Pending
- 2016-05-03 CA CA2984975A patent/CA2984975A1/en active Pending
- 2016-05-03 JP JP2018509978A patent/JP2018515138A/ja active Pending
- 2016-05-03 EP EP16719873.8A patent/EP3291679B1/en active Active
- 2016-05-03 KR KR1020207021230A patent/KR20200091499A/ko not_active Application Discontinuation
- 2016-05-03 SG SG11201708706YA patent/SG11201708706YA/en unknown
- 2016-05-03 EP EP21170379.8A patent/EP3903586A1/en active Pending
- 2016-05-03 IL IL283877A patent/IL283877B/en unknown
- 2016-05-03 AU AU2016257306A patent/AU2016257306B2/en active Active
- 2016-05-03 EP EP21213973.7A patent/EP4005386A1/en active Pending
- 2016-05-03 EP EP21170380.6A patent/EP3907285A1/en active Pending
- 2016-05-03 EP EP20155001.9A patent/EP3711488A1/en not_active Ceased
- 2016-05-03 DK DK16719873.8T patent/DK3291679T3/da active
- 2016-05-03 CN CN201680026076.9A patent/CN107667173A/zh active Pending
- 2016-05-03 IL IL310108A patent/IL310108A/en unknown
- 2016-05-03 EP EP19179004.7A patent/EP3563684A1/en active Pending
- 2016-05-03 KR KR1020237043223A patent/KR20230174291A/ko not_active Application Discontinuation
- 2016-05-03 EP EP20154858.3A patent/EP3729967A1/en not_active Withdrawn
- 2016-05-03 WO PCT/EP2016/059803 patent/WO2016177682A1/en active Application Filing
- 2016-05-03 NZ NZ738068A patent/NZ738068A/en unknown
- 2016-05-03 SI SI201631431T patent/SI3291679T1/sl unknown
- 2016-05-03 IL IL293646A patent/IL293646B1/en unknown
- 2016-05-20 US US15/160,405 patent/US9701964B2/en active Active
-
2017
- 2017-03-16 US US15/460,962 patent/US10582712B2/en active Active
- 2017-04-04 US US15/478,912 patent/US11517582B2/en active Active
- 2017-11-05 IL IL255427A patent/IL255427B/en unknown
- 2017-11-17 US US15/817,144 patent/US11612617B2/en active Active
- 2017-11-17 US US15/817,139 patent/US10524477B2/en active Active
- 2017-11-17 US US15/817,125 patent/US10506812B2/en active Active
- 2017-11-17 US US15/817,135 patent/US10463049B2/en active Active
- 2017-11-17 US US15/817,142 patent/US10624349B2/en active Active
-
2018
- 2018-01-04 US US15/862,527 patent/US20180146681A1/en not_active Abandoned
- 2018-04-10 HK HK18104678.1A patent/HK1245016A1/zh unknown
- 2018-11-15 US US16/192,746 patent/US10561148B2/en active Active
-
2019
- 2019-03-25 US US16/364,002 patent/US20190230936A1/en not_active Abandoned
- 2019-09-26 AU AU2019236694A patent/AU2019236694B2/en active Active
- 2019-09-30 US US16/588,842 patent/US20200068901A1/en active Pending
- 2019-09-30 US US16/588,754 patent/US20200077663A1/en not_active Abandoned
- 2019-11-13 US US16/682,889 patent/US20200085066A1/en active Pending
- 2019-12-19 JP JP2019228858A patent/JP2020058369A/ja active Pending
-
2020
- 2020-01-08 US US16/737,793 patent/US20200128832A1/en not_active Abandoned
- 2020-03-09 US US16/813,615 patent/US11844760B2/en active Active
- 2020-03-13 US US16/818,962 patent/US20200205416A1/en not_active Abandoned
- 2020-04-24 US US16/858,333 patent/US11147830B2/en active Active
- 2020-11-25 US US17/105,392 patent/US11400110B2/en active Active
-
2021
- 2021-05-26 US US17/331,413 patent/US20210386773A1/en not_active Abandoned
- 2021-05-26 US US17/331,422 patent/US20210283167A1/en not_active Abandoned
- 2021-05-26 US US17/331,430 patent/US20210290654A1/en active Pending
- 2021-08-03 US US17/392,827 patent/US20220233575A1/en active Pending
-
2022
- 2022-02-14 US US17/671,455 patent/US11642363B2/en active Active
- 2022-03-31 JP JP2022058903A patent/JP2022106717A/ja active Pending
- 2022-05-03 AU AU2022202944A patent/AU2022202944B2/en active Active
- 2022-05-20 US US17/750,116 patent/US20220362280A1/en active Pending
- 2022-05-20 US US17/750,101 patent/US11547716B2/en active Active
-
2023
- 2023-04-04 AU AU2023202066A patent/AU2023202066B2/en active Active
- 2023-11-03 US US18/501,825 patent/US20240082289A1/en active Pending
- 2023-12-26 JP JP2023219190A patent/JP2024038120A/ja active Pending
-
2024
- 2024-03-28 AU AU2024202021A patent/AU2024202021A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3291679T3 (da) | Ændring af mikrobielle populationer og modificering af mikrobiota | |
DK3872085T3 (da) | Stam-virussekvenser og anvendelser heraf | |
DK3827845T3 (da) | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf | |
DK3303395T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
DK3274370T3 (da) | Anti-ceacam6-antistoffer og anvendelser deraf | |
DK3170842T3 (da) | Immunologisk effektorcelle af målrettet cld18a2, fremstillingsfremgangsmåde og anvendelse deraf | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3319428T3 (da) | Herbicid sammensætning omfattende cinmethylin og imazamox | |
DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
DK3099172T3 (da) | Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3160470T3 (da) | Analoger af pridopidin, fremstilling og anvendelse heraf | |
DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
KR20180084891A (ko) | 구조 조성물 및 방법 | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
DK3288553T3 (da) | Kombinationer af cannabinoider og n-acylethanolaminer | |
DK3269809T3 (da) | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF | |
DK3394259T3 (da) | Sammensætninger og fremgangsmåder til reducering af tau-ekspression | |
DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer |